April 5, 2021
The CoVIg-19 Plasma Alliance, co-founded by Takeda Pharmaceutical and CSL Behring, said on April 2 that its investigational anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) missed the primary endpoint in a PIII study. No serious safety concerns were identified. The study, dubbed...read more